Russell Frank Company’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Russell Frank Company’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$501K	Sell	36,623 -7,150	-16%	-$103K	﹤0.01%	2455
2015 Q4	$823K	Sell	43,773 -1,053	-2%	-$22.9K	﹤0.01%	2300
2015 Q3	$841K	Buy	+44,826	New	+$762K	﹤0.01%	2269
2014 Q4	–	Sell	-113,840	Closed	-$1.44M	–	3054
2014 Q3	$1.44M	Buy	+113,840	New	+$1.1M	﹤0.01%	1896

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Russell Frank Company's CNCE Position: Q1 2016 in Review

Russell Frank Company reduced its Concert Pharmaceuticals, Inc. (CNCE) stake by 16% in Q1 2016, selling an estimated $103K and leaving 36,623 shares worth $501K. The position accounts for ﹤0.01% of the portfolio, ranked #2455.

Russell Frank Company first reported a position in CNCE in Q3 2014 and has held it in 4 quarters since. The position peaked at $1.44M in Q3 2014. 97 funds tracked by Wall St. Rank hold CNCE as of Q1 2016.

Russell Frank Company held 36,623 shares of Concert Pharmaceuticals, Inc. worth $501K as of Q1 2016.
Russell Frank Company sold 7,150 Concert Pharmaceuticals, Inc. shares in Q1 2016, an estimated $103K.
Concert Pharmaceuticals, Inc. made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2455 holding.
Russell Frank Company first reported a position in Concert Pharmaceuticals, Inc. in Q3 2014 and has held it in 4 quarters since.
Russell Frank Company's Concert Pharmaceuticals, Inc. position peaked at $1.44M in Q3 2014.
97 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.